Glucose-regulated protein 78 mediates the therapeutic efficacy of 17-DMAG in colon cancer cells

Orai1 and STIM1 are critical for cell migration and proliferation of clear cell renal cell carcinoma

(2014) Ji-Hee Kim et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Antiproliferative Effect of HSP90 Inhibitor Y306zh Against Pancreatic Cancer is Mediated by Interruption of AKT and MAPK Signaling Pathways

(2014) Nina Xue et al.   CURRENT CANCER DRUG TARGETS

Expression of GRP78 predicts taxane-based therapeutic resistance and recurrence of human gastric cancer

(2014) Lei Yang et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism

(2014) Jaime Acquaviva et al.   MOLECULAR CANCER RESEARCH

Store-Operated Ca2+ Entry (SOCE) Regulates Melanoma Proliferation and Cell Migration

(2014) Masanari Umemura et al.   PLoS One

Silencing survivin activates autophagy as an alternative survival pathway in HCC cells

(2014) Yu-Jia Chang et al.   TUMOR BIOLOGY

Colorectal cancer: From prevention to personalized medicine

(2014) Gemma Binefa   WORLD JOURNAL OF GASTROENTEROLOGY

Advances and new perspectives in the treatment of metastatic colon cancer

(2014) Gonzalo Jr Recondo   World Journal of Gastrointestinal Oncology

Glucose-regulated protein 78 silencing down-regulates vascular endothelial growth factor/vascular endothelial growth factor receptor 2 pathway to suppress human colon cancer tumor growth

(2013) Li-Jen Kuo et al.   JOURNAL OF SURGICAL RESEARCH

Hsp90 Inhibitors Promote p53-Dependent Apoptosis through PUMA and Bax

(2013) Kan He et al.   MOLECULAR CANCER THERAPEUTICS

Glucose-regulated protein 78 mediates hormone-independent prostate cancer progression and metastasis through maspin and COX-2 expression

(2013) Chun-Te Wu et al.   TUMOR BIOLOGY

Glucose-regulated protein 94 modulates the therapeutic efficacy to taxane in cervical cancer cells

(2013) Cheng-Jeng Tai et al.   TUMOR BIOLOGY

Recent Advances in Hsp90 Inhibitors as Antitumor Agents

(2012) S. Messaoudi et al.   Anti-Cancer Agents in Medicinal Chemistry

Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

(2012) L. Neckers et al.   CLINICAL CANCER RESEARCH

The Intrinsic Apoptosis Pathways as a Target in Anticancer Therapy

(2012) Verena Jendrossek   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

The network interaction of the human cytosolic 90kDa heat shock protein Hsp90: A target for cancer therapeutics

(2012) Viviane C.H. da Silva et al.   Journal of Proteomics

A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors

(2011) Simon Pacey et al.   CLINICAL CANCER RESEARCH

Adjuvant treatment of colon cancer: what is next?

(2011) Katherine Van Loon et al.   CURRENT OPINION IN ONCOLOGY

Glucose-Regulated Protein 78 (GRP78) Silencing Enhances Cell Migration but Does Not Influence Cell Proliferation in Hepatocellular Carcinoma

(2010) Yu-Jia Chang et al.   ANNALS OF SURGICAL ONCOLOGY

17-DMAG targets the nuclear factor- B family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition

(2010) E. Hertlein et al.   BLOOD

Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition

(2010) Christina Hackl et al.   BMC CANCER

GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy

(2010) Eunjung Lee et al.   INTERNATIONAL JOURNAL OF CANCER

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

(2010) J E Lancet et al.   LEUKEMIA

Glucose-Regulated Protein 78 Is a Novel Contributor to Acquisition of Resistance to Sorafenib in Hepatocellular Carcinoma

(2009) Jeng-Fong Chiou et al.   ANNALS OF SURGICAL ONCOLOGY

Role of the Unfolded Protein Response Regulator GRP78/BiP in Development, Cancer, and Neurological Disorders

(2009) Miao Wang et al.   ANTIOXIDANTS & REDOX SIGNALING

Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies

(2009) Shivaani Kummar et al.   EUROPEAN JOURNAL OF CANCER

Tanespimycin: the opportunities and challenges of targeting heat shock protein 90

(2009) Charles Erlichman   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Blockade of GRP78 sensitizes breast cancer cells to microtubules-interfering agents that induce the unfolded protein response

(2009) Jiao Wang et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Dual Targeting of HSC70 and HSP72 Inhibits HSP90 Function and Induces Tumor-Specific Apoptosis

(2008) Marissa V. Powers et al.   CANCER CELL

Oxidative Stress Plays a Critical Role in Inactivating Mutant BRAF by Geldanamycin Derivatives

(2008) Y. Fukuyo et al.   CANCER RESEARCH

Capacitative calcium entry and transient receptor potential canonical 6 expression control human hepatoma cell proliferation

(2008) Charbel El Boustany et al.   HEPATOLOGY

Overexpression of GRP78 and GRP94 are markers for aggressive behavior and poor prognosis in gastric carcinomas

(2008) Hua-chuan Zheng et al.   HUMAN PATHOLOGY

Adaptation to ER stress as a driver of malignancy and resistance to therapy in human melanoma

(2008) Peter Hersey et al.   Pigment Cell & Melanoma Research